AroCell
0.54 SEK +4.85%2 investors are following this company
AroCell specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. AroCell targets patient groups in different parts of the world. The head office is in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
AROC
Daily low / high price
0.52 / 0.55
SEK
Market cap
124.39M SEK
Turnover
222.2K SEK
Volume
414K
Latest videos
Financial calendar
Interim report
21.08.2024
Interim report
24.10.2024
Annual report
19.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Labbex Förvaltnings AB | 11.6 % | 11.6 % |
Avanza Pension | 9.4 % | 9.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Redeye: AroCell Q1 - Unrecognized and going well
AroCell AB (publ) Interim Report January 1st to March 31st, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools